Welcome to our dedicated page for Fortrea Holdings SEC filings (Ticker: FTRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Fortrea Holdings� emergence as a stand-alone CRO after its Labcorp spin-off means every quarter brings layers of new disclosures—from trial backlog shifts to milestone-based revenue. Hunting for those details in a 200-page filing is why users type “Fortrea SEC filings explained simply� or “where can I find the Fortrea quarterly earnings report 10-Q filing.�
Stock Titan fixes that pain. The moment a 10-K, 10-Q, 8-K, S-8, or DEF 14A posts to EDGAR, our AI turns it into plain English, flags changes in pass-through costs, and links footnotes to context you can act on. Need “Fortrea annual report 10-K simplified,� “Fortrea 8-K material events explained,� or a side-by-side view of Form 4 insider trades? Our platform delivers real-time updates, AI-powered summaries, and historical comparisons—so you see why an event matters, not just that it happened.
Popular use cases include:
- Tracking “Fortrea insider trading Form 4 transactions� seconds after executives file.
- Comparing enrolment cost trends straight from MD&A with our Fortrea earnings report filing analysis.
- Reviewing “Fortrea proxy statement executive compensation� without navigating 100 tables.
Pegasystems Inc. (PEGA) has filed a Form 144 indicating that insider Kenneth Stillwell plans to sell 11,147 common shares via Morgan Stanley Smith Barney on or after 4 Aug 2025. The shares have an aggregate market value of $648,670.68 and equal roughly 0.007 % of the 171,080,665 shares outstanding. The stock will be sold on NASDAQ and originates from an option exercise executed the same day.
The filing also discloses prior sales by the same insider during the last three months: 4,000 shares on 1 Aug 2025 ($230,847), 4,000 shares on 1 Jul 2025 ($210,564), and 2,000 shares on 2 Jun 2025 ($194,960), for total proceeds of about $636,371. The signer affirms no knowledge of undisclosed adverse information.
No operational, financial, or strategic updates accompany the notice; it serves solely to comply with Rule 144 requirements for the contemplated secondary sale.
The Vanguard Group filed Amendment No. 3 to Schedule 13G disclosing a 9.35 % beneficial stake in Embecta Corp (CUSIP 29082K105) as of 06/30/2025. Vanguard reports ownership of 5,466,604 common shares.
Voting authority is limited: 0 shares with sole voting power and 90,901 shares with shared voting power. Dispositive authority is broader, covering 5,317,080 shares solely and 149,524 shares shared. The filing is made under Rule 13d-1(b) with Vanguard classified as an investment adviser (Type IA), indicating a passive investment purpose. Vanguard certifies the shares were acquired in the ordinary course of business and not to influence control of Embecta.
The document is signed by Ashley Grim, Head of Global Fund Administration, on 07/29/2025.
BlackRock Portfolio Management LLC filed Amendment No. 1 to Schedule 13G for Fortrea Holdings Inc. (FTRE) covering holdings as of 30 Jun 2025. The firm reports beneficial ownership of 804,040 common shares, equal to 0.9 % of outstanding stock, placing the position well below the 5 % threshold that would trigger additional reporting requirements.
BlackRock has sole voting power over 714,353 shares and sole dispositive power over the full 804,040-share stake; it reports no shared voting or dispositive power. The filing states the shares were acquired and are held in the ordinary course of business, without intent to influence control. Because ownership is under 5 %, the filer confirms compliance with Item 5 and notes that no single client owns more than 5 % of FTRE. The document is certified by Managing Director Spencer Fleming on 15 Jul 2025.
FAQ
What is the current stock price of Fortrea Holdings (FTRE)?
What is the market cap of Fortrea Holdings (FTRE)?
What core services does Fortrea Holdings provide?
How does Fortrea generate revenue?
How does Fortrea differentiate itself in the CRO industry?
What is the significance of Fortrea's technological integration?
What industries does Fortrea primarily serve?
How extensive is Fortrea's global presence?
How does Fortrea ensure regulatory and quality compliance?
